EVIDENCE PROFILE / PUBLISHED
Tirzepatide
Tirzepatide is a GIP- and GLP-1-receptor agonist. Approved delivery systems, concentrations, excipients, and labeling are not interchangeable with a research vial. Large product-development programs support specific branded uses; ongoing studies do not turn every metabolic claim into an approved indication.
Evidence at a glance
- Human
- Not rated
- Animal/cell
- Not rated
- Approved medicine
- Approved product existsAn approved U.S. product (Mounjaro), for a specific formulation and use.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Trials examine glycemic, weight, cardiovascular, sleep-apnea, and other metabolic outcomes in defined populations.
Identity
Tirzepatide is a GIP- and GLP-1-receptor agonist. Approved delivery systems, concentrations, excipients, and labeling are not interchangeable with a research vial.
Biological mechanism or research interest
Trials examine glycemic, weight, cardiovascular, sleep-apnea, and other metabolic outcomes in defined populations.
Verified approved human uses
FDA-approved Mounjaro injection is labeled for glycemic control in adults and children aged 10 years and older with type 2 diabetes. Other branded indications require their own current labels. This catalogue vial is not an approved medicine.
Investigational human evidence
Large product-development programs support specific branded uses; ongoing studies do not turn every metabolic claim into an approved indication.
Popular claims versus demonstrated findings
Claims must not be generalized across diabetes, obesity, cardiovascular risk, or other conditions without the matching product, population, and outcome evidence.
Human versus animal or cell evidence
Receptor pharmacology and animal findings help explain effects but labels depend on clinical trials.
Limitations and known risks
The Mounjaro label includes a boxed thyroid C-cell-tumor warning from rodent findings and gastrointestinal, pancreatitis, gallbladder, kidney-volume-depletion, hypoglycemia, and hypersensitivity risks.
